InVision Medical Technology GTM brain

category

market profile

• text: Echo labs face high interpretation workloads and variability, while cardiac amyloidosis may go unrecognized.
• text: Hospital adoption depends on clinical evidence, regulatory clearance, workflow integration and reimbursement, not model performance alone.

personas

• title: Cardiovascular service line director
  pains:

  • Needs to improve echo lab throughput while justifying investment and reimbursement.
  • Cannot adopt another tool that requires major changes to imaging workflow.
• title: Echocardiography lab director or cardiologist
  pains:

  • Manual ejection fraction measurement consumes time and can vary between readers.
  • Subtle signs of cardiac amyloidosis may be missed during routine echo interpretation.
• title: Health system imaging IT and security leader
  pains:

  • Must integrate AI with existing DICOM, PACS and clinical systems.
  • Needs assurance about patient data residency and deployment options.

icp

• text: US hospitals and health systems with established echocardiography labs and significant echo volume.
• text: Cardiology practices or academic medical centers seeking AI-supported LVEF assessment and cardiac amyloid detection.
• text: Provider organizations with DICOM-compatible cardiac imaging and PACS or CVIS workflows.

message pillars

• text: Lead with the clinical research and validation behind the product.
• text: Fit AI into existing imaging infrastructure.
• text: Offer flexible deployment for clinical IT requirements.

objections

• objection: Does this work in actual clinical workflows?
  response: Review the blinded randomized LVEF trial and product-specific FDA clearances with clinical leaders, then evaluate local workflow fit.
• objection: Will integration expose protected health information?
  response: Evaluate the on-premise and cloud options with security and review the actual data processing agreement.
• objection: Can our hospital recover the cost?
  response: Review the product-specific reimbursement pathway and payer requirements with revenue cycle staff; reimbursement is not guaranteed.

competitors

• name: Ultromics
  website: https://www.ultromics.com/
  why: EchoGo analyzes routine echocardiograms for cardiac amyloidosis and heart failure.
• name: Us2.ai
  website: https://us2.ai/
  why: Automates echocardiography measurements and reporting and offers overlapping disease detection.

influencers

• name: David Ouyang
  url: https://douyang.github.io/
  why: Co-founder and clinical researcher working on AI echocardiography and prospective trials.

keywords

• AI echocardiography software
• automated ejection fraction measurement
• cardiac amyloidosis echo AI
• echo lab workflow automation
• AI cardiac ultrasound diagnosis
• DICOM echocardiography AI
• cardiac imaging reimbursement

voice

• Clinical and evidence-led
• Enterprise procurement-aware
• Confident and precise

signals

• text: A health system is seeking to reduce echo interpretation workload or standardize LVEF measurements.
• text: A cardiology service is developing an amyloidosis detection program or examining reimbursement for AI-assisted detection.
• text: An imaging IT team is evaluating vendor-neutral DICOM AI integrations.

stack

• DICOM
• PACS
• CVIS
• Epic

pricing

motion

channels

• clinical publications
• medical conferences
• LinkedIn
• partnerships
• press

confidence

Founders

• name: David Ouyang
  title: Founder
  role: Founder
  bio: MD 2014, UCSF Internal Medicine Residency 2017, Stanford Cardiology Fellowship 2020, Stanford Cardiologist, Cedars Sinai Medical Center
• name: Bryan He
  title: Founder
  role: Founder
  bio: PhD Computer Science 2022, Stanford University BS Computer Science 2015, California Institute of Technology